Subject characteristics at time of analysis
| Subjecta | Age (yr) | Duration of HIV infection (yr)b | Current therapyc | Virus load (copies/ml) | CD4 count (cells/μl) | Total HIV-specific CD4 response (SFC/106 cells)d | No. of recognized peptidese |
|---|---|---|---|---|---|---|---|
| Acute-Rx | |||||||
| AC20 | 4 | 4 | HAART | <50 | 1,223 | 195 | 1 |
| AC21 | 40 | 4 | HAART | <50 | 489 | 1,105 | 7 |
| AC32 | 38 | 3 | HAART | <50 | 571 | 310 | 2 |
| AC34 | 34 | 3 | HAART | <50 | 443 | 205 | 0 |
| AC63 | 38 | 2 | HAART | <50 | 732 | 140 | 0 |
| AC82 | 44 | 1 | HAART | <50 | 1,082 | 270 | 3 |
| AC87 | 39 | 4 | HAART | <50 | 917 | 815 | 11 |
| Acute-STI | |||||||
| AC02 | 48 | 5 | STI-no HAART | 5,790 | 714 | 560 | 3 |
| AC03 | 36 | 5 | STI-no HAART | 2,850 | 805 | 1,610 | 7 |
| AC05 | 44 | 5 | STI-no HAART | 12,900 | 361 | 890 | 24 |
| AC06 | 42 | 5 | STI-no HAART | 23,000 | 427 | 2,750 | 18 |
| AC10 | 36 | 5 | STI-no HAART | 267 | 755 | 2,030 | 19 |
| AC14 | 50 | 4 | STI-no HAART | 2,300 | 503 | 1,875 | 18 |
| AC15 | 46 | 5 | STI-no HAART | 17,800 | 535 | 3,120 | 29 |
| AC26 | 49 | 4 | STI-no HAART | 82,600 | 660 | 1,480 | 12 |
| AC46 | 52 | 2 | STI-no HAART | 2,975 | 888 | >14,610 | 36 |
| Chronic-Rx | |||||||
| CRT1 | 33 | 1 | HAART | <50 | 172 | 80 | 1 |
| CRT2 | 36 | 13 | HAART | <50 | 579 | 120 | 0 |
| CRT3 | 40 | 1 | HAART | <50 | 609 | 580 | 2 |
| CRT4 | 52 | 3 | HAART | <50 | 146 | 60 | 0 |
| CRT5 | 34 | 3 | HAART | <50 | 1,163 | 180 | 1 |
| Chronic-no Rx | |||||||
| CRU1 | 51 | 1 | None | 16,300 | 899 | 1,360 | 2 |
| CRU2 | 55 | 1 | None | 32,800 | 1,050 | 1,540 | 9 |
| CRU3 | 29 | 1 | None | 52,700 | 371 | 295 | 4 |
| CRU4 | 34 | 2 | None | 23,500 | 1,051 | 230 | 3 |
| CRU5 | 38 | 6 | None | 257,000 | 28 | 0 | 0 |
| CRU6 | 38 | 2 | None | 10,791 | 239 | 1,365 | 8 |
| Controller-LTNP | |||||||
| CO1 | 34 | 3 | None | 212 | 1,082 | 1,320 | 9 |
| CO2 | 44 | 4 | None | 1,620 | 798 | 130 | 0 |
| CO5 | 37 | 6 | None | <50 | 732 | 250 | 3 |
| CO6 | 50 | 7 | None | 1,140 | 672 | 745 | 3 |
| CO7 | 54 | 4 | None | 390 | 742 | 230 | 6 |
| LT4 | 50 | 10 | None | <50 | 832 | 4,540 | 34 |
| LT6 | 37 | 15 | None | 754 | 832 | 1,175 | 22 |
| LT9 | 40 | 14 | None | <50 | 1,801 | 640 | 7 |
| LT14 | 48 | 7 | None | <50 | 1,340 | 880 | 6 |
↵a Subjects AC20, CRT3, CRU5, CRU6, and LT14 are females. All other individuals are males.
↵b Indicates years of documented HIV-1 infection.
↵c HAART defined as regimen containing at least three drugs.
↵d Sum of responses to the positive peptide pools in IFN-γ ELISPOT in SFC per 106 CD8-depleted PBMC. As each peptide is in two pools, only the responses to the pools with contiguous overlapping peptides were used for the calculation of the total response.
↵e Number of confirmed responses to individual peptides in IFN-γ ELISPOT.